Company Description
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom.
The company’s lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections.
It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab.
The company was founded in 2003 and is headquartered in Miami, Florida.
| Country | United States |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 105 |
| CEO | Robert W. Duggan |
Contact Details
Address: 601 Brickell Key Drive, Suite 1000 Miami, Florida 33131 United States | |
| Phone | 650 460 8308 |
| Website | summittxinc.com |
Stock Details
| Ticker Symbol | SMMT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001599298 |
| CUSIP Number | 86627T108 |
| ISIN Number | US86627T1088 |
| Employer ID | 37-1979717 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mahkam Zanganeh D.D.S., M.B.A. | Co-Chief Executive Officer, President and Director |
| Robert W. Duggan | Co-Chief Executive Officer and Executive Chairman |
| Prof. Dame Kay Davies DBE, FRS CBE | Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor |
| Bhaskar Anand | Chief Accounting Officer and Head of Finance |
| Abby Guzman Murphy | Head of Human Resources |
| Divya Chari | Head of Global Clinical Operations |
| Dave Gancarz | Chief Business and Strategy Officer |
| Dr. Betty Y. Chang Ph.D. | Head of Research, Oncology and Inflammation |
| Dr. Fong Clow | Chief Biometrics Officer |
| Shelley D. Spray | Chief Education and Brand Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 30, 2024 | 10-Q | Quarterly Report |
| Oct 30, 2024 | 8-K | Current Report |
| Sep 26, 2024 | D | Notice of Exempt Offering of Securities |
| Sep 19, 2024 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Sep 13, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Sep 12, 2024 | 8-K | Current Report |
| Sep 9, 2024 | 8-K | Current Report |
| Aug 6, 2024 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Aug 6, 2024 | 10-Q | Quarterly Report |
| Aug 6, 2024 | 8-K | Current Report |